Aurinia Pharmaceuticals (AUPH) Institutional Ownership
13F filers reported holding 8.8% of Aurinia Pharmaceuticals (AUPH) shares as of Sep 30, 2026, across 129 filers.
- Held by 13F filers
- 8.8%
- Sep 30, 2026
- 13F filers
- 129
- quarter ended Sep 30, 2026
- 13F value
- $190.7M
- 11.8M shares
- Quarter's fund flow
- Mild accumulation
- 16 new · 14 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Robertson Stephen P. | Chief Legal Officer | Disposed · Open-market sale | 11,867 | $15.97 | ↗ |
| Sep 10, 2026 | Robertson Stephen P. | Chief Legal Officer | Disposed · Open-market sale | 11,939 | $15.95 | ↗ |
| Aug 21, 2026 | Robertson Stephen P. | Chief Legal Officer | Disposed · Open-market sale | 20,975 | $16.97 | ↗ |
| Jun 4, 2026 | Goetz Kathleen | director | Acquired · Grant / award | 23,931Director Stock Option (right to buy) | — | ↗ |
| Jun 4, 2026 | Bailey Jeffrey Allen | director | Acquired · Grant / award | 23,931Director Stock Option (right to buy) | — | ↗ |
| Jun 4, 2026 | Johnson Craig A | director | Acquired · Grant / award | 23,931Director Stock Option (right to buy) | — | ↗ |
| Jun 4, 2026 | Nova Tina Susan | director | Acquired · Grant / award | 23,931Director Stock Option (right to buy) | — | ↗ |
| Jun 2, 2026 | TANG KEVIN C | Chief Executive Officer | Acquired · Open-market buy | 206,005Common Shares | $15.28 | ↗ |
| Jun 2, 2026 | TANG KEVIN C | Chief Executive Officer | Acquired · Other | 10,000Short Put Options (potential obligation to buy) | $1.65 | ↗ |
| Jun 1, 2026 | TANG KEVIN C | Chief Executive Officer | Acquired · Open-market buy | 343,521Common Shares | $15.28 | ↗ |
| Jun 1, 2026 | TANG KEVIN C | Chief Executive Officer | Acquired · Open-market buy | 99Common Shares | $15.34 | ↗ |
| May 29, 2026 | TANG KEVIN C | Chief Executive Officer | Acquired · Open-market buy | 2,299Common Shares | $15.35 | ↗ |
| May 29, 2026 | TANG KEVIN C | Chief Executive Officer | Acquired · Open-market buy | 262,682Common Shares | $15.31 | ↗ |
| May 18, 2026 | Cole Ryan | Chief Operating Officer | Acquired · Grant / award | 116,144 | — | ↗ |
| May 18, 2026 | Cole Ryan | Chief Operating Officer | Acquired · Grant / award | 70,230Employee Stock Option (right to buy) | — | ↗ |
| May 18, 2026 | Robertson Stephen P. | Chief Legal Officer | Acquired · Grant / award | 115,541 | — | ↗ |
| May 18, 2026 | Hearne Michael S | Chief Financial Officer | Acquired · Grant / award | 116,144 | — | ↗ |
| May 18, 2026 | Hearne Michael S | Chief Financial Officer | Acquired · Grant / award | 70,230Employee Stock Option (right to buy) | — | ↗ |
| Mar 6, 2026 | Keenan Greg | SVP, Chief Medical Officer | Disposed · Tax withholding | 8,069 | $14.32 | ↗ |
| Mar 3, 2026 | TANG KEVIN C | director | Acquired · Open-market buy | 184,208Common Shares | $14.22 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Aurinia Pharmaceuticals do institutions hold?
13F filers reported holding 8.8% of Aurinia Pharmaceuticals' shares as of Sep 30, 2026, across 129 filers.
How many 13F filers hold Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals was held by 129 13F filers as of Sep 30, 2026.
Not investment advice.

